Elohim Pharmaceuticals LLC is categorized under Wholesale Pharmaceutical Products in Houston, TX and active since 2012.
Elohim Pharmaceuticals LLC was established in 2012, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Wholesale Pharmaceutical Products business, which does work in the B2B market, and is classified as a Wholesale Pharmaceutical Products, under code number 424210 by the NAICS.
If you are seeking more information, feel free to contact Joseph Agbebaku at the company’s single location by writing to 1917 Gessner Road, Houston, Texas TX 77080 or by phoning (713) 827-1202. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Elohim Pharmaceuticals LLC |
| Contact Person: | Joseph Agbebaku |
| Address: | 1917 Gessner Road, Houston, Texas 77080 |
| Phone Number: | (713) 827-1202 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2012 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Wholesale Pharmaceutical Products |
| SIC Code: | 5122 |
| NAICS Code: | 424210 |
| Share This Business: |
Elohim Pharmaceuticals LLC was started in 2012 to provide professional Wholesale Pharmaceutical Products under the SIC code 5122 and NAICS code 424210. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Joseph Agbebaku for inquiries that concern Elohim Pharmaceuticals LLC by calling the company number (713) 827-1202, as your correspondence is most welcome. Additionally, the physical location of the single location of Elohim Pharmaceuticals LLC can be found at the coordinates 29.807292,-95.545407 as well as the street address 1917 Gessner Road in Houston, Texas 77080.
For its online presence, you may visit Elohim Pharmaceuticals LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.